Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes, acute myeloid leukemia as well as additional hematologic and solid tumor malignancies. Aprea Therapeutics Inc. is based in Boston, Massachusetts....
+See More2018-09-17 12:40:00 Monday ET
Nobel Laureate Robert Shiller's long-term stock market indicator points to a recent peak. His cyclically-adjusted P/E ratio (or CAPE) accounts for long-
2019-06-30 12:37:00 Sunday ET
AYA Analytica finbuzz podcast channel on YouTube June 2019 In this podcast, we discuss several topical issues as of June 2019: (1) Federal Reserve h
2017-07-13 08:35:00 Thursday ET
President Donald Trump has announced that a major Apple iPhone upstream supplier, Foxconn Technology Group (aka Hon Hai Precision Group), will invest $10 bi
2018-03-27 07:33:00 Tuesday ET
CNBC's business anchorwoman Becky Quick interviews Nobel Laureate Joseph Stiglitz on the current trade war between America and China. As America imposes
2023-06-19 10:31:00 Monday ET
A brief biography of Dr Andy Yeh (PhD, MFE, MMS, BMS, FRM, and USPTO patent accreditation) Dr Andy Yeh is responsible for ensuring maximum sustainable me
2019-01-10 17:31:00 Thursday ET
The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be